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Edited by Horst FeldmannAbstract The properties of the glutamate receptor subunits 1–4
(GluR1–4) are inﬂuenced by the alternative splicing of two
homologous and mutually exclusive exons ﬂip and ﬂop. The ﬂip
form is most abundant during early development, while the ﬂop
form is dominant in adults. From transfections with a GluR2
mini-gene we show that ﬂip is the preferred splice form in all
tested cell lines, but coexpression of the SR-proteins ASF/SF2
and SC35 increases the ﬂop to ﬂip splice ratio. The increased
ﬂop incorporation depends on ASF/SF2- and SC35-dependent
enhancer elements located in the ﬂop exon, which stimulate the
splicing between the ﬂop exon and the preceding exon 13.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Alternative pre-mRNA splicing plays a central role in regu-
lation of gene-expression in higher eukaryotes. More than half
of the human gene products undergo alternative splicing [1],
considerably enlarging the complexity of the proteome [2].
Regulation of alternative splicing is complex, and a single
alternative splicing event is in many cases under the control
of several exonic and intronic cis-elements, termed enhancers
and silencers, which typically function as recognition sites for
trans-acting splicing factors that stimulate or repress splicing
(e.g. [3–6] or reviewed in [7]). One of the best characterised
classes of splicing factors is the family of serine/arginine-rich
(SR) proteins, which are involved in both constitutive and
alternative splicing [8,9]. SR-proteins activate splicing of
many regulated exons via binding to exonic enhancer ele-
ments (see, for example, [10–13]) from where they are pro-
posed to recruit factors of the splicing machinery to the
adjacent splice sites [9,14]. Individual SR-proteins exhibit dis-
tinct substrate speciﬁcities, but since RNA recognition se-
quences for the diﬀerent SR-proteins are degenerate andAbbreviations: ASF/SF2, alternative splicing factor/splicing factor 2;
SC35, Spliceosome component of 35 kDa; AMPA, a-amino-3-hydro-
xy-5-methyl-4-isoazolepropionic acid; GluR, glutamate receptor;
SR-protein, serine/arginine-rich protein
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doi:10.1016/j.febslet.2005.06.044overlapping [15–18], the prediction of SR-protein dependent
enhancers is uncertain.
The glutamatergic system is by far the most abundant
excitatory neurotransmitter system in the mammalian brain.
There are diﬀerent subtypes of ionotropic glutamate recep-
tors, and the AMPA- (a-amino-3-hydroxy-5-methyl-4-isoaz-
olepropionic acid) subtype plays a central role in the fast
transmission. The AMPA receptors are glutamate gated ion
channels formed as tetrameric complexes of the subunits
GluR1–4 (or GluRA-D) (reviewed in [19,20]). The genes
encoding the subunits GluR1–4 all contain a pair of highly
homologous exons, ﬂip and ﬂop, which are spliced in a mutu-
ally exclusive manner (Fig. 1) [21]. Receptors formed of sub-
units of either the ﬂip or ﬂop splice variants exhibit diﬀerent
kinetic and pharmacological properties, where the ﬂip vari-
ants desensitise slower than the ﬂop forms and are also more
sensitive to compounds, which block desensitisation, such as
cyclothiazide [21,22]. Furthermore, the ﬂip/ﬂop alternative
splicing is regulated in a tissue and developmental stage spe-
ciﬁc manner with subunit speciﬁc variations [21,23–25]. For
the GluR2 subunit, the ﬂip splice form dominates at the
embryonic state and in early life, while the ﬂop form takes
over in a tissue-speciﬁc manner at later stages [25]. So far,
very little is known about the molecular basis for regulation
of the complex ﬂip/ﬂop splicing.
In this report, we examine the importance of the SR-proteins
ASF/SF2 and SC35 in regulation of the GluR2 ﬂip/ﬂop splic-
ing by transient transfections in the neuroblastoma cell line
N2a. We show that both proteins shift the ﬂip/ﬂop splicing
balance, inducing a higher ﬂop to ﬂip ratio. Furthermore, by
site-directed mutagenesis, we identify cis-regulatory elements
within the ﬂop exon that respond to the splicing factors.2. Materials and methods
2.1. Plasmid construction and mutagenesis
The R2L mini-gene sequence was ampliﬁed from genomic DNA
puriﬁed from rat liver by methods previously described [26] using the
primers 5 0 CGC GCG CTC GAG CTT TTT CTG CAG AGA TCT
AAA ATC GCA GTG and 5 0 CGC GCG CTC GAG CCT CGT
TCC TAC CCC CTA AAT TTT AAC and the Expande Long Tem-
plate PCR System (Boehringer Mannheim). The PCR-product was
cloned as an XhoI fragment into pcDNA3 (Invitrogen). Point muta-
tions of R2L were made by site-directed mutagenesis by consecutive
overlapping PCRs.
The ASF/SF2, SC35, and U2AF65 expression plasmids were kindly
provided by G.R. Screaton: The cDNAs were cloned into the multiple
cloning site of the pCDM8 vector and expressed from the CMV pro-
moter. The U1 70k expression plasmid (pBC-U170k [27]) was a gift
from D.J. Keene.ation of European Biochemical Societies.
Fig. 2. Flip is preferentially included in N2a and HEK 293 cells. (A)
Schematic representation of the R2L mini-gene including exon 13 to
exon 16 of the rat GluR2 gene. Black arrows show the approximate
position of primers used for RT-PCR and the grey arrow shows the
position of the primer used in the primer extension assay. (B) RT-PCR
performed on RNA from pR2L transfected N2a or HEK293 cells. The
positions of PCR-products corresponding to splice products contain-
ing either ﬂip or ﬂop and to splice products excluding both exons are
indicated. Minus lanes are reactions performed in the absence of
reverse transcriptase. (C) Primer extension assay using the PCR-
product marked with an asterisk (Fig. 2B) as template for extension of
a 32P labelled primer in the presence of ddCTP to distinguish between
ﬂip and ﬂop products. The positions of the primer extension products
corresponding to ﬂip, ﬂop and exon-skipping products are shown on
the right. The percentage of ﬂop inclusion was calculated from the
intensity of the ﬂop signal relative to the sum of the intensities of the
ﬂop and ﬂip signals, as quantitated by PhosphorImaging.
Fig. 1. (A) Schematic representation of the genomic organisation of
the alternative exons of the glutamate receptors subunits. Exons 12 to
17 are shown (not drawn to scale). Exons are represented by boxes and
introns by lines. The mutually exclusive splicing pathways are shown
by dotted lines. (B) Alignment of the sequences of the ﬂip and ﬂop
exons of the rat GluR2. Putative recognition sites for ASF/SF2 (grey)
and SC35 (black) are indicated by brackets.
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The mouse neuroblastoma cell line N2a was cultured at 37 C and
7.5% CO2 in Dulbeccos modiﬁed Eagles medium with glutamax
(Invitrogen) supplemented with 5% (v/v) fetal bovine serum (FBS)
and 1% penicillin-streptomycin (100 units/ml–100 lg/ml). Transfection
was performed in 6-well plates at 70–90% conﬂuence with 1 lg of mini-
gene and 1 lg of SR-protein expression plasmid using Lipofectaminee
2000 (Invitrogen) as recommended by the manufacturers. RNA was
puriﬁed after 48 h by the TRIzol method (Invitrogen).
2.3. Reverse transcription (RT) and PCR
Superscript RT II (Invitrogen) was used for reverse transcription of
the RNA with a GluR2 exon 16 speciﬁc primer (Ex16anti; 5 0 CCG
GGA CTT GTA GCA GAA CTC) at 42 C for 1 h. cDNA was ampli-
ﬁed by PCR using a T7 primer and the Ex16anti primer. The ﬂip and
ﬂop PCR-products are equal in length and diﬀer at only 36 of 590 posi-
tions, suggesting a linearity of the ﬂip/ﬂop ratio during the RT-PCR
ampliﬁcation. To verify this assumption, various ratios of GluR2 ﬂip
and ﬂop cDNAs were analysed by PCR and primer extension, where
we found a linear correlation between the ratios measured by the assay
and the actual ratio, and we obtained the same results independently of
the number of cycles in the ampliﬁcation (data not shown).
2.4. Primer extension
A PCR-product of 590 nucleotides corresponding to either ﬂip or
ﬂop containing splice products was puriﬁed after agarose gel electro-
phoresis and used as template for extension of primer 5 0 [32P]ACA
CCT AAA GGA TCC TCA T, which was radiolabelled with
[c-32P]ATP (3000 Ci/mmol; Pharmacia Biotech) using T4 polynucleo-
tide kinase (New England Biolabs). The primer was extended by
Thermo Sequenase (Amersham) as recommended by the manufacturers
in the presence of 0.3 mM ddCTP and 0.03 mM dGTP, dATP, and
dTTP. The extension products were separated on a 15% denaturing
polyacrylamide gel and the bands were quantiﬁed by PhophorImaging.
The level of ﬂop inclusion was determined as the intensity of the signal
obtained from extension by 10 nucleotides (ﬂop) relative to the sum of
the intensities of the signals obtained from primers extended by 10 and 7
(ﬂip) nucleotides. For samples containing PCR-products of splice vari-
ants including both ﬂip and ﬂop (e.g. when cotransfected with SC35)
special caution must be taken in the primer extension to correct for con-
tamination of the double inclusion product, which otherwise will result
in an overestimate of ﬂop including products. The contamination was
quantiﬁed using a primer annealing in ﬂop and extending into ﬂip
(for the double inclusion product) or exon 16 (for the ﬂop splice form).
2.5. Q-PCR
Q-PCR was performed on a Q-PCR machine (Biorad) in the pres-
ence of the ﬂuorescent CYBR green. Each cycle was 30 s at 95 C,
30 s at 58 C and 30 s at 72 C. The primers were 1: 5 0 CAA TGA
ACG AGT ACA TCG AGC AGA, 2: 5 0 ACT GTG CAT CGC
TGC TGC TTA CTT TGT, 3: 5 0 CAG TAA CTC TGC AGG CATTAC CAA, 4: 5 0 AAT CTG CTC ACC CTG TCT GAC AAG, 5:
5 0 CTC ACC GTT TGC TTA GGC CAA ATG, 6i: 5 0 ACT GGT
CTT TTC CTT ACT TCC CGA, 6o: 5 0 ACT GGT CTT TTC CTT
GGA ATC ACC. PCRs were performed with four primer pairs,
1 + 2, 1 + 2, 4 + 6o and 4 + 6i. To determine the relative eﬃciency of
the primer pairs, each set of primers was normalized to a standard pri-
mer pair: Inserts corresponding to the four PCR products were cloned
into pcDNA3. Q-PCR reactions were performed with either the splice
speciﬁc primer pair or a primer pair annealing to the amp gene in
pcDNA3. The ratios between the two ampliﬁcations were used as
the eﬃciency of the splice speciﬁc primers pair.3. Results
3.1. Flip is preferably included in most cell types
To study the regulation of the alternative splicing of the ﬂip
and ﬂop exons in GluR2, we PCR ampliﬁed and isolated a frag-
ment of the rat GluR2 gene, which contains exon 13 through
exon 16, and cloned it into the expression-vector pcDNA3.
The resulting construct, pR2L (Fig. 2), was transfected into dif-
ferent cell lines, and RNA was isolated. By RT-PCR, using
primes annealing to a vector speciﬁc sequence and to exon 16,
we selectively ampliﬁed RNA transcribed from the pR2L
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590 bp correspond to the splice products including either ﬂip or
ﬂop and the other shorter fragments (475 bp) to splice products
where both exons were excluded. The latter (exon skipping)
product was not detected in RNA isolated from brain tissue
(data not shown). The splice forms were observed in RNA from
both the mouse neuroblastoma cell line, N2a and in HEK 293
cells (Fig. 2B), whereas a product corresponding to inclusion
of both alternative exons was not detected, emphasising the mu-
tual exclusion of the ﬂip and ﬂop exons in these systems.
After control experiments, which showed that fragments
containing either ﬂip or ﬂop were ampliﬁed with equal eﬃcien-
cies (see Section 2), the PCR-product corresponding to the
spliced RNAs including either ﬂip or ﬂop (590 bp) was gel-
puriﬁed, and the ﬂip to ﬂop splicing ratio was determined by
primer extension (Fig. 2C). The extension primer was designed
to anneal in exon 13 and, after addition of the polymerase and
dATP, dTTP, dGTP and ddCTP, to be extended into the adja-
cent exon where the extension terminates at the most proximal
C. For ﬂip this results in a 7 nucleotide extension, while 10
nucleotides are added for the ﬂop form. Surprisingly, extension
of 12 nucleotides corresponding to the exon-skipping product
was also observed in the gel-puriﬁed 590 bp band. Subcloning
and subsequent sequencing conﬁrmed the presence of exon-
skipping DNA in the band.
For the alternatively spliced forms containing one alterna-
tive exon, the ﬂip exon was preferably inserted, resulting in
ﬂop inclusion levels of 15% and 18% in N2a and HEK 293
cells, respectively. We examined other cell types including
HeLa and the neuronally derived cell lines NT2, SH-SY5Y,
IMR-32, and SK-N-MC (data not shown), but the ﬂip variant
was incorporated to a similar or higher extend in all of these
lines, suggesting that ﬂop inclusion might be speciﬁc for a sub-
set of neurons.Fig. 3. ASF/SF2 and SC35 induce ﬂop inclusion. pR2L was co-
transfected with plasmids encoding ASF/SF2, SC35, U2AF65 or
U170k, and RNA was examined by RT-PCR (A) and primer extension
(B) as described in Fig. 2. The fraction of ﬂop inclusion products was
calculated as described in Fig. 2 and bars (C) show the results from
three parallel experiments. Error bars denote standard deviations
(\P < 0.05).3.2. Expression of the SR-proteins ASF/SF2 and SC35 increase
ﬂop-inclusion
SR-proteins regulate a variety of alternatively spliced exons
and to examine the contribution of the SR-proteins to the reg-
ulation of the ﬂip/ﬂop splice ratio, the pR2L mini-gene was
cotransfected with plasmids encoding either the SR-protein
ASF/SF2 or SC35, and the splice pattern of the transcript from
pR2L was examined as described above (Fig. 3). Cotransfec-
tion with the ASF/SF2 expression plasmid decreased the exon
skipping product relative to the ﬂip or ﬂop containing product
as visualised by a decrease in the relative intensity of the exon-
skipping product (Fig. 3A). This eﬀect was even more pro-
nounced when SC35 was coexpressed with pR2L, since the
band corresponding to the exon-skipping product almost dis-
appeared. Concurrently, an additional band corresponding
to a product including both the ﬂip and the ﬂop exons ap-
peared (Fig. 3A). Thus, coexpression of SC35 reduced the mu-
tual exclusivity of the ﬂip/ﬂop splicing. Furthermore,
coexpression of either ASF/SF2 or SC35 with pR2L led to ele-
vated ﬂop inclusion, increasing the amount of exon-inclusion
products containing ﬂop from 17.4 ± 1.7% to 44.9 ± 2.0%
and 35.1 ± 8.0%, respectively (Fig. 3B and C). We also tested
the SR-related proteins U2AF65 involved in the U2AF com-
plex and U1 70k, which is a component of U1 snRNP. Neither
showed any eﬀect on the level of exon inclusion (Fig. 3A),
whereas both stimulated ﬂip inclusion, as the ﬂop inclusion ra-tio decreased to 8.1 ± 0.3% for U2AF65 and 10.0 ± 2.5% for
U1 70K (Fig. 3B and C).
3.3. ASF/SF2 and SC35 activate exon 13 to ﬂop splicing
Splicing of either ﬂip or ﬂop requires two steps, splicing to
exon 13 and splicing to exon 16, and due to the mutual exclu-
sivity of ﬂip and ﬂop, the ﬁrst splicing event will deﬁne the
resulting splice form. To examine the splicing pathways that
lead to production of ﬂip or ﬂop inclusion, we quantiﬁed the
steady state levels of the four splice intermediates by Q-PCR
with primers that selectively amplify each of the intermediates.
Thus, for the splice intermediates where splicing to exon 13
precedes the splicing to exon 16, primers 1 + 2 detect the ﬂop
form and primers 1 + 3 the ﬂip form (Fig. 4A). For the splice
intermediates where splicing to exon 16 precedes the splicing to
exon 13, two primers 6i and 6o with 3
0 extensions speciﬁc for
ﬂip and ﬂop were used to prevent ampliﬁcation of splicing
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Fig. 4. ASF/SF2 and SC35 activate exon 13 to ﬂop splicing. Q-PCR
was used to quantify the steady state levels of the four splicing
intermediates that possibly are formed during splicing of either ﬂop or
ﬂip variants. Four diﬀerent primer pairs speciﬁcally amplify the
diﬀerent splicing intermediates. (A) The approximate positions of
primer annealing of the primers used. Primer 6 was designed with 3 0
extension for either ﬂop (6o) or ﬂip (6i). (B) Q-PCRs with the indicated
primers were performed on cDNA from N2a cells transfected as
indicated, and the relative amounts of splicing intermediates were
calculated. The splicing intermediates ampliﬁed by each primer pair
are schematically illustrated at the right (the fragments ampliﬁed by
the primers only cover a small part of the intermediates illustrated) and
are as follows: Primer pair 5 + 6i: intermediates spliced between exon
16 and ﬂip; 6o + 4: intermediates spliced between exon 16 and ﬂop;
1 + 3: intermediates spliced between exon 13 and ﬂip, and 1 + 2:
intermediates spliced between exon 13 and ﬂop.
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4 was used in combination with 6o to detect the ﬂop form and
primer 5 in combination with 6i for the ﬂip form. The amount
of each splicing intermediate was calculated in arbitrary units
(Section 2), and the relative amount of each intermediate is
shown in Fig. 4B. The most abundant splicing intermediate
was ﬂip spliced to exon 16 (5 + 6i)(63%), while the other possi-
ble ﬂip intermediate, where the ﬂip exon had spliced to exon 13
(1 + 3), was nearly absent (5%), indicating that the ﬁrst splicing
step leading to production of ﬂip variants is usually splicing to
exon 16. Alternatively, initial splicing between ﬂip and exon 13
may cause the next step to proceed very rapidly, preventing
accumulation of the intermediate. In contrast, the two splicing
intermediates giving rise to ﬂop variants were present at similar
levels (20% for intermediates spliced between ﬂop and exon 13
(1 + 2) and 13% for intermediates spliced between ﬂop and
exon 16 (4 + 6o)), indicating that ﬂop variants are produced
equally often by both splicing pathways.
To examine if any speciﬁc step of the splicing pathway is af-
fected by ASF/SF2 or SC35, we isolated RNA from cells trans-
fected with pR2L and ASF/SF2 or SC35 expression plasmids.
Coexpression with ASF/SF2 or SC35 increased the relative
amount of intermediates spliced between exon 13 and ﬂop
from 20% to 50% and 61%, respectively (Fig. 4B, 1 + 2), indi-
cating that they markedly activate this splicing step, which is in
accordance with the observation that both ASF/SF2 and SC35
induce ﬂop inclusion.For coexpression with SC35, intermediates including both
ﬂip and ﬂop were identiﬁed with primer pair 4 + 6, but not
with the 1 + 3 primer pair, indicating that these variants are
mainly produced when splicing to exon 16 is the ﬁrst step (data
not shown).3.4. Mutation of putative ASF/SF2 and SC35 binding sites
abolishes the stimulatory eﬀect on ﬂop inclusion
To identify possible exon enhancer elements through which
ASF/SF2 and SC35 mediate stimulation of ﬂop inclusion, we
scanned the ﬂop exon for sequence elements with similarity
to known ASF/SF2 and SC35 recognition sites paying special
attention to sequences which were not conserved in the ﬂip
exon (Fig. 1B). Three putative ASF/SF2 sites were identiﬁed
based on these criteria; two motifs in each end of the ﬂop exon
resembling the degenerate ASF/SF2-responsive consensus se-
quence, SRSASGA (S = G/C, R = G/A), which was identiﬁed
in a functional SELEX [16], and one element similar to the
ASF/SF2 recognition sequence, AGGACAGAGC, identiﬁed
in a conventional SELEX experiment [17]. Three putative ﬂop
selective SC35 sites were also identiﬁed. One site located in the
5 0 end of ﬂop is similar to an SC35-dependent enhancer iden-
tiﬁed in the ß-globin transcript (UGCCGUU) [28] and two se-
quence elements in the 3 0 end show similarity to the SELEX
identiﬁed consensus sequence, AGGAGAU [15]. The putative
recognition elements were disrupted by site-directed mutations
interfering with one or two recognition sites (R2L21, R2L23,
R2L24 and R2L25) (Fig. 5A). Only nucleotides that diﬀer
between ﬂip and ﬂop were mutated.
Since the absolute levels of the ﬂip/ﬂop splice ratios diﬀered
between transfection rounds, the given results represent the
mean of triplicates in a single transfection, but the qualitative
eﬀects of both cotransfections and mutations remained con-
stant between transfection rounds.
The mutations in R2L21, R2L24 and R2L25 all reduced the
basal level of ﬂop inclusion by 2 to 4-fold (from 22.9 ± 1.3% to
9.8 ± 1.2% for R2L21, from 8.7 ± 1.2% to 2.0 ± 1.0% for
R2L24 and from 7.3 ± 1.1% to 4.1 ± 0.5% for R2L25), indicat-
ing that the mutations disrupt enhancers. Flop inclusion was
unaﬀected by the R2L23 mutation (Fig. 5C).
The eﬀects of ASF/SF2 and SC35 on the mutant forms of the
GluR2 mini-gene were examined after coexpression in N2a cells
(Fig. 5B andC).CotransfectionwithASF/SF2 andSC35 expres-
sion plasmids increased the inclusion of ﬂop in the wildtype con-
struct (Fig. 3Cand5C) andpromoted splicing in general (Fig. 3B
and 5B). ASF/SF2, however, did not stimulate the inclusion of
the ﬂop exon of R2L24 and R2L25 (Fig. 5C), indicating that
these mutations disrupt ASF/SF2-dependent enhancers. SC35
did not stimulate ﬂop inclusion ofR2L21 andR2L25, indicating
that the mutated sequences include SC35-dependent enhancer
elements. The low basal level of ﬂop inclusion of mutants
R2L21, R2L24 and R2L25 is consistent with the idea that
endogenous SC35 or ASF/SF2 might stimulate ﬂop inclusion.
In summary, we have identiﬁed three ﬂop elements important
for ASF/SF2 or SC35 stimulated ﬂop inclusion.4. Discussion
Here, we show that ASF/SF2 and SC35 can regulate the ﬂip/
ﬂop splice ratio of the GluR2 transcript in N2a cells. Both ASF/
Fig. 5. Mutations of putative SR-protein recognition elements abolish SR-protein mediated ﬂop inclusion. (A) Representation of mutants R2L21,
R2L23, R2L24 and R2L25. The ﬂop sequence of interest is shown and putative SR-protein binding sites are underlined. Mutated nucleotides are
shown in italics. (B) RT-PCR on RNA from N2a cell transfected with the indicated mini-genes and SR-protein expression plasmids. (C)
Quantiﬁcation of ﬂop inclusion determined by primer extension in three experiments as described in Fig. 3. *P < 0.01 compared to R2L, **P < 0.05
compared to non-cotransfected mutant.
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exon resulting in increased ﬂop to ﬂip ratio. We extend these
ﬁndings by showing that speciﬁc point mutations within the
ﬂop exon interfere with the SR-protein mediated ﬂop inclusion.
To determine the eﬀect of the SR-proteins on the splicing
pathway we measured the steady state levels of the four diﬀer-
ent splicing intermediates by Q-PCR. Cotransfection with
ASF/SF2 or SC35 increased the amount of the splicing inter-
mediates where exon 13 is spliced to the ﬂop exon prior to
the splicing to exon 16, indicating that the SR-proteins stimu-
late this splicing event speciﬁcally. Since the assay measures the
relative ratios between the steady state levels of the intermedi-
ates, the increased level of the exon 13 to ﬂop intermediate
could also results from a reduction in the rate of splicing be-
tween ﬂop and exon 16 (the second splicing event). However,
we ﬁnd that less likely since ASF/SF2 and SC35 stimulate ﬂop
inclusion and SR-proteins generally act as splicing activators.
Stimulated splicing of intron 13 might result from activation
of either the 5 0 splice site or the 3 0 splice site. Both ASF/SF2
and SC35 stimulate splicing of some 5 0 splice sites [29,30],
and it is possible that the increased ﬂop inclusion results from
ASF/SF2 or SC35 mediated activation of the 5 0 splice site of
intron 13 followed by splicing to the proximal 3 0 splice site
(ﬂop). However, the mutagenesis of putative enhancer ele-
ments within the ﬂop exon indicate that ASF/SF2 and SC35
recognise the ﬂop exon and stimulate its 3 0 splice site, as also
described for many other alternative exons (for example [31–
34] and [9]).The mutations tested were designed to disrupt elements with
resemblance to the published recognition sequences for either
ASF/SF2 or SC35. The mutants R2L21, R2L24 and R2L25
all show decreased ﬂop inclusion as compared to the wildtype,
indicating that the mutations interfere with enhancer elements.
The R2L24 mutation furthermore abolishes the eﬀect of
cotransfection with pASF/SF2, indicating that the disrupted
enhancer is ASF/SF2-dependent. This mutation disrupts an
AGGAGAGUGC sequence resembling the AGGACRRAGC
element selected by ASF/SF2 in a SELEX experiment [17],
suggesting that this element is the recognition site for ASF/
SF2. Likewise, the R2L21 mutation abolishes the SC35-depen-
dent stimulation of ﬂop, indicating that an SC35-dependent
enhancer has been disrupted by the mutation. This is in agree-
ment with it changing a UGCGGUU sequence very similar to
an SC35-dependent enhancer (UGCCGUU) identiﬁed in the
ß-globin transcript [28]. The R2L25 mutation abolishes both
ASF/SF2 and SC35 mediated stimulation of ﬂop, suggesting
that the mutated sequence contains both ASF/SF2- and
SC35-dependent enhancers. In accordance, the mutation dis-
rupts elements similar to SELEX derived recognition se-
quences for both proteins, namely an AGGAGAU element
selected by SC35 [15] and an SRSASGA sequence selected
by ASF/SF2 [16]. The mutated elements are therefore most
likely to be the enhancer elements.
In summary, our results suggest that ASF/SF2 and SC35
stimulate ﬂop inclusion via binding to enhancer elements with-
in the exon, and that ﬂop contains at least two ASF/SF2-
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Stimulation of ﬂop inclusion by SC35 is disrupted by either
of the mutations in R2L21 and R2L25, suggesting that the
activity of SC35 depends on the presence of both elements.
Likewise, ASF/SF2-dependent stimulation of ﬂop inclusion
depends on the presence of both the elements mutated in
R2L24 and R2L25.
SR-proteins are ubiquitously expressed, and they contribute
to the inclusion of many constitutive exons [7,9], but in vitro
and transfection assays have shown that they also aﬀect tissue
speciﬁc alternative splicing events. Importantly, it was recently
shown that heart-speciﬁc knock-out of ASF/SF2 leads to mis-
splicing of a subset of transcripts undergoing heart-speciﬁc
splicing at a special point in heart development [35], clearly
supporting the idea that ASF/SF2 functions as a regulator of
tissue-speciﬁc splicing. The tissue speciﬁcity is likely to be
achieved by a combination of varied expression levels of the
SR-proteins and counteracting factors, such as hnRNPA1
[36–38] and regulation of their activities by both kinases
[18,39–42] and other regulating factors, such as SRrp86 [43]
or p32 [44].
Interestingly, splicing of the mouse GluR2 transcript was
sensitive to cotransfection with plasmids expressing the SR-
related protein NSSR [45], which appears to be expressed at
higher levels in neurons [45–47]. Two splice variants of the pro-
tein (NSSR1 and NSSR2) had opposite eﬀects on ﬂip inclusion
[45], but the mechanism of splicing regulation was not studied
in further detail, and it remains to be clariﬁed if the splicing ef-
fect is direct. NSSR, also identiﬁed as TASR [48], SRp38 [47]
and SRrp40 [49], represses splicing and antagonises ASF/SF2-
and SC35-mediated splice activation in vitro [47,49]. There-
fore, it would be interesting to examine whether ﬂip/ﬂop
splicing regulation by NSSR and by ASF/SF2 and SC35 is
somehow interconnected.
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